Marina Biotech, Inc.  

(Public, OTCMKTS:MRNA)   Watch this stock  
Find more results for NASDAQ:MRNA
-0.035 (-6.87%)
May 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.47 - 0.51
52 week 0.47 - 1.30
Open 0.50
Vol / Avg. 110,669.00/33,748.00
Mkt cap 12.18M
P/E 1.54
Div/yield     -
EPS 0.31
Shares 25.64M
Beta -0.04
Inst. own 0%
May 14, 2015
Q1 2015 Marina Biotech Inc Earnings Release
Mar 9, 2015
Marina Biotech Inc at ROTH Conference

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -1295.40%
Operating margin - -596.20%
EBITD margin - -704.00%
Return on average assets 19.24% -76.39%
Return on average equity - -
Employees 1 -
CDP Score - -


3830 Monte Villa Pkwy
BOTHELL, WA 98021-7266
United States - Map
+1-425-9083600 (Phone)
+1-302-6745266 (Fax)

Website links


Marina Biotech, Inc., is a pharmaceutical and biotechnology company. The Company is focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company has acquired and in-licensed and further developed nucleic acid chemistry and delivery-related technologies to form an integrated drug discovery platform. The Company’s Nucleic acid-based therapeutics targets two types of RNA: coding RNA and non-coding RNA. The Company continues to seek to establish collaborations and strategic partnerships with pharmaceutical and biotechnology companies. The Company is engaged in therapeutic and scientific of delivery of nucleic acid-based therapeutics in the treatment of human disease including orphan diseases.

Officers and directors

J. Michael French Chairman of the Board, President, Chief Executive Officer
Age: 55
Daniel E. Geffken Interim Chief Financial Officer
Age: 58
Stefan D. Loren Ph.D. Lead Independent Director
Age: 50
Philip C. Ranker Director
Age: 54
Trading Activity - Yahoo Finance
Joseph W. Ramelli Independent Director
Age: 46
Donald A. Williams Independent Director
Age: 56